Impact of early tumor shrinkage on clinical outcome in wild‐type‐<scp>KRAS</scp> colorectal liver metastases treated with cetuximab

Ye, Lechi; Ye, Wei; Zhu, Dexiang; Chen, Tao; Xu, Jiacheng

doi:10.1111/jgh.12847

Cited by 15 publications

(17 citation statements)

References 25 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective analysis of 132 patients with unresectable colorectal liver metastases (wild-type-KRAS) receiving chemotherapy (FOLFIRI or mFOLFOX6) with or without cetuximab ETS was also estimated [36]. Irrespective of treatment arm, ETS P 20% at week 8 was associated with superior PFS and OS (chemotherapy + cetuximab: 38.0 versus 18.7 months, p < 0.001; CT alone: 30.6 versus 17.7 months, p = 0.003).…”

Section: Ets In Patients Receiving Chemotherapy Plus Egfrtargeting Mabsmentioning

confidence: 99%

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Heinemann

Stintzing

Modest

et al. 2015

European Journal of Cancer

160

145

View full text Add to dashboard Cite

Section: Ets In Patients Receiving Chemotherapy Plus Egfrtargeting Mabsmentioning

confidence: 99%

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Heinemann

Stintzing

Modest

et al. 2015

European Journal of Cancer

160

145

View full text Add to dashboard Cite

“…The CRYSTAL and OPUS studies showed that in patients with KRAS wild‐type tumours cetuximab increased the rate of complete resections of liver metastases, from 4.5% to 9.8% and 2.4% to 4.7%, respectively. Other studies estimate that the rate of metastatic resections can be increased with cetuximab plus CT when the patient's management is coordinated with liver surgeons, increasing the probability of R0 resections to 18% …”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of Cetuximab as a treatment strategy for metastatic colon cancer in Peru: chemotherapy/Cetuximab versus chemotherapy alone

Bolaños-Díaz

Sanabria

Farfán-Tello³

et al. 2018

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objective To evaluate cost‐effectiveness – from a local perspective – of cetuximab when it is added to conventional chemotherapy for the treatment of metastatic colon cancer. Methods A Markov model was structured based on the systematic review of the evidence and the opinion of local experts. The economic model consists of three health states: (a) progression free survival (PFS), (b) progressive disease (PD) and (c) death. The basic measure to determine the effectiveness of the intervention was the Quality Adjusted Life Year (QALY); however, other intermediate outcomes of impact on survival were considered, such as ‘R0 metastases resections’ and ‘early tumour shrinkage’ (ETS). Quarterly cycles were considered with a time horizon of 19 quarters (approximately 5 years). The analysis perspective was based on the Ministry of Health (MoH). Key findings The cost per quality adjusted life year (cost/QALY) for chemotherapy + cetuximab treatment (CT/Cet) with respect to the baseline strategy approaches S/. 20 078 (equivalent to 1 Gross Domestic Product per capita [GDP‐pc]). The probabilistic analysis of the ICER (Incremental Cost‐Effectiveness Ratio) shows that, in all the cases, the CT/Cet strategy becomes more cost‐effective with a payment threshold of S/. 30 000 (1.5 GDP‐pc). Likewise, the acceptability curves showed that, from a threshold of S/. 20 000, the intervention with cetuximab becomes more cost‐effective than chemotherapy alone (CT). Conclusions The cost/QALY was S/. 20 078 (1 local GDP‐pc) for the intervention with CT plus cetuximab. Other results of clinical relevance, such as ‘additional R0‐resections’, ‘additional ETS cases’, ‘disease progressions avoided’ and ‘deaths avoided’ also favour the combination treatment.

show abstract

“…In this setting, Ye L.C. et al [11] and Douillard J.Y. [12] demonstrated that macroscopic liver resection was significantly associated with early tumor response on intravenous chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Early tumor shrinkage could thus represent an important clinical objective for rapid symptoms relief , identification of best candidates for LM conversion-to-resection [11,12] and ultimately overall survival (OS) improvement.…”

Section: Introductionmentioning

confidence: 99%

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

Bouchahda

Boige

Smith

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

2016) Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer Care, 68. pp. 163-172 Permanent WRAP URL: http://wrap.warwick.ac.uk/85119 Copyright and reuse:The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. Publisher's statement:"This is the peer reviewed version of the following article: Bouchahda, Mohamed, Boige, Valérie, Smith, Denis, Karaboué, Abdoulaye, Ducreux, Michel, Hebbar, Mohamed, Lepère, Céline, Focan, Christian, Guimbaud, Rosine, Innominato, Pasquale F. et al.. (2016) Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer Care, 68. pp. 163-172 which has been published in final form at http://dx.doi.org/10.1016/j.ejca.2016.09.011 This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." A note on versions:The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription. within a multicenter conversion-to-resection medico-surgical strategy. Confirmation is warranted for decision-making. Protocol numbersEUDRACT 2007-004632-24 NCT00852228 KEY WORDS:Early tumor response, colorectal cancer, liver metastases, hepatic artery infusion, triplet chemotherapy. ACKNOWLEDGEMENTS:We sincerely acknowledge the contribution of the patients who participated in this trial and all our colleagues and staff at the participating institutions.

show abstract

Impact of early tumor shrinkage on clinical outcome in wild‐type‐KRAS colorectal liver metastases treated with cetuximab

Abstract: ETS may serve as a predictor of favorable outcome in patients with wild-type KRAS CLM receiving cetuximab plus chemotherapy.

Cited by 15 publications

References 25 publications

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Cost-effectiveness of Cetuximab as a treatment strategy for metastatic colon cancer in Peru: chemotherapy/Cetuximab versus chemotherapy alone

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

Contact Info

Product

Resources

About